|
1
|
Dion L, Carton I, Jaillard S, et al: The
Landscape and Therapeutic Implications of Molecular Profiles in
Epithelial Ovarian Cancer. J Clin Med. 9:22392020. View Article : Google Scholar
|
|
2
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boyault C, Sadoul K, Pabion M and Khochbin
S: HDAC6, at the crossroads between cytoskeleton and cell signaling
by acetylation and ubiquitination. Oncogene. 26:5468–5476. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cao J, Lv W, Wang L, Xu J, Yuan P, Huang
S, He Z and Hu J: Ricolinostat (ACY-1215) suppresses proliferation
and promotes apoptosis in esophageal squamous cell carcinoma via
miR-30d/PI3K/AKT/mTOR and ERK pathways. Cell Death Dis. 9:8172018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Shin D and Kwon SH: Histone
deacetylase 6 plays a role as a distinct regulator of diverse
cellular processes. FEBS J. 280:775–793. 2013.PubMed/NCBI
|
|
9
|
Yee AJ, Bensinger WI, Supko JG, Voorhees
PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE,
Burke JN, et al: Ricolinostat plus lenalidomide, and dexamethasone
in relapsed or refractory multiple myeloma: A multicentre phase 1b
trial. Lancet Oncol. 17:1569–1578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Putcha P, Yu J, Rodriguez-Barrueco R,
Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M,
Castro V, Llobet-Navas D, et al: HDAC6 activity is a non-oncogene
addiction hub for inflammatory breast cancers. Breast Cancer Res.
17:1492015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng U, Wang Z, Pei S, Ou Y, Hu P, Liu W
and Song J: ACY-1215 accelerates vemurafenib induced cell death of
BRAF-mutant melanoma cells via induction of ER stress and
inhibition of ERK activation. Oncol Rep. 37:1270–1276. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li S, Liu X, Chen X, Zhang L and Wang X:
Histone deacetylase 6 promotes growth of glioblastoma through
inhibition of SMAD2 signaling. Tumour Biol. 36:9661–9665. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Corno C, Arrighetti N, Ciusani E, Corna E,
Carenini N, Zaffaroni N, Gatti L and Perego P: Synergistic
interaction of histone deacetylase 6- and MEK-inhibitors in
castration-resistant prostate cancer cells. Front Cell Dev Biol.
8:6102020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee DH, Won HR, Ryu HW, Han JM and Kwon
SH: The HDAC6 inhibitor ACY 1215 enhances the anticancer activity
of oxaliplatin in colorectal cancer cells. Int J Oncol. 53:844–854.
2018.PubMed/NCBI
|
|
15
|
Santo L, Hideshima T, Kung AL, Tseng JC,
Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et
al: Preclinical activity, pharmacodynamic, and pharmacokinetic
properties of a selective HDAC6 inhibitor, ACY-1215, in combination
with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amengual JE, Johannet P, Lombardo M, Zullo
K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen
J, et al: Dual targeting of protein degradation pathways with the
selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in
lymphoma. Clin Cancer Res. 21:4663–4675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang P, Almeciga-Pinto I, Jarpe M, van
Duzer JH, Mazitschek R, Yang M, Jones SS and Quayle SN: Selective
HDAC inhibition by ACY-241 enhances the activity of paclitaxel in
solid tumor models. Oncotarget. 8:2694–2707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ryu HW, Shin DH, Lee DH, Won HR and Kwon
SH: A potent hydroxamic acid-based, small-molecule inhibitor A452
preferentially inhibits HDAC6 activity and induces cytotoxicity
toward cancer cells irrespective of p53 status. Carcinogenesis.
39:72–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Won HR, Ryu HW, Shin DH, Yeon SK, Lee DH
and Kwon SH: A452, an HDAC6-selective inhibitor, synergistically
enhances the anticancer activity of chemotherapeutic agents in
colorectal cancer cells. Mol Carcinog. 57:1383–1395. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bitler BG, Wu S, Park PH, Hai Y, Aird KM,
Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ III, et al:
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell
Biol. 19:962–973. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reed SM and Quelle DE: p53 acetylation:
Regulation and consequences. Cancers (Basel). 7:30–69. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Geissmann Q: OpenCFU, a new free and
open-source software to count cell colonies and other circular
objects. PLoS One. 8:e540722013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
North BJ, Almeciga-Pinto I, Tamang D, Yang
M, Jones SS and Quayle SN: Enhancement of pomalidomide anti-tumor
response with ACY-241, a selective HDAC6 inhibitor. PLoS One.
12:e01735072017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ray A, Das DS, Song Y, Hideshima T, Tai
YT, Chauhan D and Anderson KC: Combination of a novel HDAC6
inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor
immunity and cytotoxicity in multiple myeloma. Leukemia.
32:843–846. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanno K, Kanno S, Nitta H, Uesugi N, Sugai
T, Masuda T, Wakabayashi G and Maesawa C: Overexpression of histone
deacetylase 6 contributes to accelerated migration and invasion
activity of hepatocellular carcinoma cells. Oncol Rep. 28:867–873.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cho HY, Lee SW, Jeon YH, Lee DH, Kim GW,
Yoo J, Kim SY and Kwon SH: Combination of ACY-241 and JQ1
synergistically suppresses metastasis of HNSCC via regulation of
MMP-2 and MMP-9. Int J Mol Sci. 21:68732020. View Article : Google Scholar
|
|
28
|
Ryu HW, Shin DH, Lee DH, Choi J, Han G,
Lee KY and Kwon SH: HDAC6 deacetylates p53 at lysines 381/382 and
differentially coordinates p53-induced apoptosis. Cancer Lett.
391:162–171. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cong J, Liu R, Hou J, Wang X, Jiang H and
Wang J: Therapeutic effect of bevacizumab combined with paclitaxel
and carboplatin on recurrent ovarian cancer. J BUON. 24:1003–1008.
2019.PubMed/NCBI
|
|
30
|
Coleman RL, Brady MF, Herzog TJ, Sabbatini
P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley
DM, et al: Bevacizumab and paclitaxel-carboplatin chemotherapy and
secondary cytoreduction in recurrent, platinum-sensitive ovarian
cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A
multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.
18:779–791. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mottamal M, Zheng S, Huang TL and Wang G:
Histone deacetylase inhibitors in clinical studies as templates for
new anticancer agents. Molecules. 20:3898–3941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee DH, Kim GW and Kwon SH: The
HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma
and synergizes with ibrutinib in follicular lymphoma. Mol Carcinog.
58:944–956. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Won HR, Lee DH, Yeon SK, Ryu HW, Kim GW
and Kwon SH: HDAC6 selective inhibitor synergistically enhances the
anticancer activity of immunomodulatory drugs in multiple myeloma.
Int J Oncol. 55:499–512. 2019.PubMed/NCBI
|
|
35
|
Kim GW, Yoo J, Won HR, Yeon SK, Lee SW,
Lee DH, Jeon YH and Kwon SH: A452, HDAC6-selective inhibitor
synergistically enhances the anticancer activity of
immunomodulatory drugs in IMiDs-resistant multiple myeloma. Leuk
Res. 95:1063982020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim GW, Lee DH, Yeon SK, Jeon YH, Yoo J,
Lee SW and Kwon SH: Temozolomide-resistant glioblastoma depends on
HDAC6 activity through regulation of DNA mismatch repair.
Anticancer Res. 39:6731–6741. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zuco V, De Cesare M, Cincinelli R, Nannei
R, Pisano C, Zaffaroni N and Zunino F: Synergistic antitumor
effects of novel HDAC inhibitors and paclitaxel in vitro and in
vivo. PLoS One. 6:e290852011. View Article : Google Scholar : PubMed/NCBI
|
